Recombinant proteins are a fresh gene mashup that creates DNA. The processing of large quantities of unaltered and altered human and mammalian proteins is possible thanks to DNA sequencing. Clone DNA sequences typically encode an enzyme or protein known to be functional and are use to create recombinant proteins. Recombinant proteins are use to develop novel treatments for serious chronic disorders like anemia, cancer, diabetes, multiple sclerosis, and other rare diseases. Recombinant DNA technology, a special technique, is required to produce recombinant proteins. The market for recombinant proteins will grow rapidly, with a CAGR of 10.12%, from its current value of $1.65 billion in 2021 to $3.93 billion by 2030.
Market Dynamics
The continual development of proteins as a crucial therapeutic option in a variety of human diseases has been made possible by the numerous advancements in pharmaceutical learning and pharmaceutical development. The market for recombinant proteins for research purposes is predicted to grow quickly due to rising inclination and rising R&D spending on biological drugs, among other significant developments. One of the key value drivers for research-based pharmaceutical companies is the development of novel medications that address unmet patient needs. Additionally, the growing emphasis on protein therapeutics, personalized medicine, and industry-academia collaborations are key factors driving the market’s expansion.
It is anticipate that as research activity rises, funding for research will become more readily available, and demand for and production of recombinant proteins, particularly immune response proteins relate to COVID-19, will rise. Additionally, COVID-19 had a significant impact on the life sciences sector. The businesses that sell products specifically for COVID-19 benefitte. However, the disruption of clinical trials and the closure of the laboratory severely hamper research and development efforts.
Trends and Opportunities
From a technical perspective, developments in a variety of fields assisting or related to recombinant protein synthesis have contributed to the expansion of the recombinant protein market. The development of alternative cell lines and enhanced cell culture systems, as well as alternative expression technologies such as mammalian cell, baculovirus, and E. coli expression, have all sped up and streamlined the production of recombinant proteins. The output of the product has also increased in a shorter period due to improvements in bioreactor systems.
Additionally, market participants are anticipate to invest in the region due to the aging population, rising income levels, better healthcare infrastructure, rising healthcare spending, and expanding advantages of low-cost manufacturing in APAC nations. Additionally, it is anticipate that the markets for recombinant clotting proteins and recombinant non-glycosylated proteins will grow at respective CAGRs of 7.6% and 8.9%.
Segmentation analysis
Product Insight
In 2021, the product segment ruled the whole industry. More than 65.70 percent of total revenue was generate by this segment in the same year. The segment is expect to keep its top spot throughout the forecast period while growing at the second-fastest rate. The widespread use of these products, among others, in cancer, HIV/AIDS, COVID-19. Immunology, and neuroscience has contribute to the segment’s expansion. Growth factors and cytokines also have a big impact on cancer research.
Application Insights
In 2021, the therapeutics sector dominated the global market and contributed to the highest revenue share of more than 33.90%. As diseases like cancer, genetic disorders, and immune diseases become more common. There will likely be greater demand for protein-based treatments.
End-use Insight
In 2021, the pharmaceutical and biotechnology companies segment had the highest revenue share. The bio-manufacturers have invested millions of dollars in R&D to expand their product pipeline, develop new technologies, and improve bioprocessing tools due to the trend toward biologics and biosimilars.
Regional Insights
In 2021, North America was the highest market, with a share of more than 33.85%, dominating. The global industry due to growing research expenditures. The accessibility of healthcare infrastructure, and the presence of numerous industry players. Recombinant protein therapies are in high demand, and they’re one of the tested treatments for these disorders and one of. The reasons why chronic diseases are spreading throughout the region.
Key Players analysis
ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Crown Bioscience, Inc., BioVision, Inc., Sigma Aldrich Company Ltd. Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., HumanZyme, Inc., and GenScript Biotech Corporation are significant market participants.
